tbuckley/cabot-search huggingface dataset:
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Authors: Ana Lluch, Carlos H. Barrios, Laura Torrecillas, Manuel Ruiz-Borrego, Jose Bines, Jose Segalla, Ángel Guerrero-Zotano, Jose A. García-Sáenz, Roberto Torres, Juan de la Haba, Elena García-Martínez, Henry L. Gómez, Antonio Llombart, Javier Salvador Bofill, José M. Baena-Cañada, Agustí Barnadas, Lourdes Calvo, Laura Pérez-Michel, Manuel Ramos, Isaura Fernández, Álvaro Rodríguez-Lescure, Jesús Cárdenas, Jeferson Vinholes, Eduardo Martínez de Dueñas, Maria J. Godes, Miguel A. Seguí, Antonio Antón, Pilar López-Álvarez, Jorge Moncayo, Gilberto Amorim, Esther Villar, Salvador Reyes, Carlos Sampaio, Bernardita Cardemil, Maria J. Escudero, Susana Bezares, Eva Carrasco, Miguel Martín
Journal: Journal of Clinical Oncology (2019)

Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients with early TNBC.Eligible patients were those with operable, node-positive-or node negative with tumor 1 cm or greater-TNBC, with prior anthracycline- and/or taxane-containing chemotherapy. After central confirmation of TNBC status by immunohistochemistry, patients were randomly assigned to either capecitabine or observation. Stratification factors included institution, prior taxane-based therapy, involved axillary lymph nodes, and centrally determined phenotype (basal v nonbasal, according to cytokeratins 5/6 and/or epidermal growth factor receptor positivity by immunohistochemistry). The primary objective was to compare disease-free survival (DFS) between both arms.Eight hundred seventy-six patients were randomly assigned to capecitabine (n = 448) or observation (n = 428). Median age was 49 years, 55.9% were lymph node negative, 73.9% had a basal phenotype, and 67.5% received previous anthracyclines plus taxanes. Median length of follow-up was 7.3 years. DFS was not significantly prolonged with capecitabine versus observation [hazard ratio (HR), 0.82; 95% CI, 0.63 to 1.06; P = .136]. In a preplanned subgroup analysis, nonbasal patients seemed to derive benefit from the addition of capecitabine with a DFS HR of 0.53 versus 0.94 in those with basal phenotype (interaction test P = .0694) and an HR for overall survival of 0.42 versus 1.23 in basal phenotype (interaction test P = .0052). Tolerance of capecitabine was as expected, with 75.2% of patients completing the planned 8 cycles.This study failed to show a statistically significant increase in DFS by adding extended capecitabine to standard chemotherapy in patients with early TNBC. In a preplanned subset analysis, patients with nonbasal phenotype seemed to obtain benefit with capecitabine, although this will require additional validation.
Environmental Health Practice Challenges and Research Needs for U.S. Health Departments
Authors: Bryan W. Brooks, Justin A. Gerding, Elizabeth Landeen, Eric Bradley, Timothy Callahan, Stephanie Cushing, Fikru Hailu, Nancy Hall, Timothy Hatch, Sherise Jurries, Martin A. Kalis, Kaitlyn R. Kelly, Joseph P. Laco, Niki Lemin, Carol McInnes, Greg Olsen, Robert Stratman, Carolyn White, Steven Wille, John Sarisky
Journal: Environmental Health Perspectives (2019)

Background: Environmental health (EH) professionals, one of the largest segments of the public health workforce, are responsible for delivery of essential environmental public health services. The challenges facing these professionals and research needs to improve EH practice are not fully understood, but 26% of EH professionals working in health departments of the United States plan to retire in 5 y, while only 6% of public health students are currently pursuing EH concentrations. Objectives: A groundbreaking initiative was recently launched to understand EH practice in health departments of the United States. This commentary article aims to identify priority EH practice challenges and related research needs for health departments. Methods: A horizon scanning approach was conducted in which challenges facing EH professionals were provided by 1,736 respondents working at health departments who responded to a web-based survey fielded in November 2017. Thematic analyses of the responses and determining the frequency at which respondents reported specific issues and opportunities identified primary EH topic areas. These topic areas and related issues informed focus group discussions at an in-person workshop held in Anaheim, California. The purpose of the in-person workshop was to engage each of the topic areas and issues, through facilitated focus groups, leading to the formation of four to five related problem statements for each EH topic. Discussion: EH professionals are strategically positioned to diagnose, intervene, and prevent public health threats. Focus group engagement resulted in 29 priority problem statements partitioned among 6 EH topic areas: a) drinking water quality, b) wastewater management, c) healthy homes, d) food safety, e) vectors and public health pests, and f) emerging issues. This commentary article identifies priority challenges and related research needs to catalyze effective delivery of essential environmental public health services for common EH program areas in health departments. An unprecedented initiative to revitalize EH practice with timely and strategic recommendations for student and professional training, nontraditional partnerships, and basic and translational research activities is recommended. https://doi.org/10.1289/EHP5161
Legality of Sterilization
Authors: R P Bergen
Journal: BMJ (1960)

Sterilization for therapeutic purposes is not prohibited in any state, but is prohibited for birth control purposes in Connecticut, Kansas, and Utah. Sterilization for certain eugenic purposes (e.g., feeble-mindedness, mental illness) is authorized in 28 states. Voluntary sterilization for any reason with limitation concerning age and consent is permitted by statute in Georgia, North Carolina, and Virginia. Since sterilization is a serious and usually irreversible procedure, hospitals are advised to take special precautions to avoid liability. Consent of both patient and spouse should be obtained. Hospitals have the authority to require consultation or approval by a committee as a prerequisite to a sterilization operation.
Abstract 12607: Change in Small Dense Low-Density Lipoprotein Particle Number Relates to Change in Coronary Plaque Burden Independent of Traditional Cardiovascular Risk Factors in Psoriasis
Authors: Aparna Sajja, Youssef Elnabawi, Martin Playford, Amit Dey, Justin Rodante, Jacob Groenendyk, Aditya Joshi, Aarthi S Reddy, Gregory Sanda, Nevin Varghese, Charlotte Harrington, Heather Teague, Yvonne Baumer, Marcus Y Chen, David A Bluemke, Alan T Remaley, Nehal N Mehta
Journal: Circulation (2018)

Introduction: Psoriasis (PSO) is a chronic inflammatory disorder associated with increased cardiovascular (CV) risk and lipoprotein dysfunction. Small dense LDL particle number (s-LDLp) is now reco...
Association of Single Nucleotide Polymorphisms of Interleukins-1β, -6, and -12B with Contact Lens Keratitis Susceptibility and Severity
Authors: Nicole A. Carnt, Mark D.P. Willcox, Scott Hau, Linda L. Garthwaite, Victoria E. Evans, Cherry F. Radford, John K.G. Dart, Subhabrata Chakrabarti, Fiona Stapleton
Journal: Ophthalmology (2012)
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis
Authors: Pierpaolo Trimboli, Lorenzo Scappaticcio, Giorgio Treglia, Leo Guidobaldi, Massimo Bongiovanni, Luca Giovanella
Journal: Endocrine Pathology (2019)
The Phosphoinositide-Binding Protein p40phox Regulates NADPH Oxidase Activation Rather Than Assembly during FcγIIA Receptor-Induced Phagocytosis.
Authors: Wei Tian, Xing Jun Li, Natalie D. Stull, Chang-Il Suh, Sergio Grinstein, MIchael B. Yaffe, Simon J. Atkinson, Mary C. Dinauer
Journal: Blood (2006)
VH and VL Genes in Hairy Cell Leukemia Reveal a Dynamic On-Going Modification of the Surface B-Cell Receptor.
Authors: Francesco Forconi, T. Amato, D. Raspadori, S. S. Sahota, M. A. Dell’Aversano, M. Tassi, D. Rossi, M. Bocchia, M. Lenoci, L. Rigacci, F. Zaja, G. Gaidano, L. Leoncini, Francesco Lauria
Journal: Blood (2005)
TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression
Authors: Can Li, Reinaldo Franqui-Machin, Jiliang Xia, Gregory S. Thomas, Yogesh Jethava, Fangping Chen, Ivana Frech, Guido J. Tricot, Fenghuang Zhan
Journal: Blood (2019)
Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.
Authors: Deirdre O’Mahony, John C. Morris, Leslie Moses, Diana O’Hagan, Wendy Gao, Maryalice Stetler-Stevenson, Margaret Taylor, Luz Hammershaimb, Thomas A. Waldmann, John E. Janik
Journal: Blood (2005)
Bone Marrow-Derived Aldehyde Dehdrogenase Expressing Cells Possess Endothelial Progenitor Function in Addition to Hematopoietic Repopulating Ability and Aid in Blood Flow Recovery after Acute Ischemic Injury.
Authors: Benjamin J. Capoccia, Louisa Wirthlin, Rebecca Shepherd, Kevin O’Dell, Jan A. Nolta, Daniel C. Link, David A. Hess
Journal: Blood (2005)
Progress Toward Precision Medicine in Frontline Treatment of Metastatic Renal Cell Carcinoma
Authors: Nirmish Singla
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).
Authors: Jochen Greiner, Krzysztof Giannopoulos, Li Li, Peter Liebisch, Christiane Wendl, Jinfei Chen, Mark Ringhoffer, Phillipe Guillaume, Gerd Ritter, Hartmut Doehner, Michael Schmitt
Journal: Blood (2005)
Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Imatinib: Introducing the Concept of Confirmed Molecular Response.
Authors: Francesca Palandri, Gianantonio Rosti, Ilaria Iacobucci, Nicoletta Testoni, Fausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, Bruno Martino, Daniela Cilloni, Fabrizio Pane, Marco Gobbi, Tamara Intermesoli, Fabio Stagno, Adele Capucci, Giovanni Martinelli, Michele Baccarani
Journal: Blood (2007)
Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations
Authors: Barbara J. Turner, Andrea Rochat, Sarah Lill, Raudel Bobadilla, Ludivina Hernandez, Aro Choi, Juan A. Guerrero
Journal: Annals of Internal Medicine (2019)

Hepatitis C virus (HCV) disproportionately affects disadvantaged communities.To examine processes and outcomes of Screen, Treat, Or Prevent Hepatocellular Carcinoma (STOP HCC), a multicomponent intervention for HCV screening and care in safety-net primary care practices.Mixed-methods retrospective analysis.5 federally qualified health centers (FQHCs) and 1 family medicine residency program serving low-income communities in diverse locations with largely Hispanic populations.Persons born in 1945 through 1965 (baby boomers) who had never been tested for HCV and were followed through May 2018.The Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) model guided implementation and evaluation. Test costs were covered for uninsured patients.All practices tested patients for anti-HCV antibody (anti-HCV) and HCV RNA. For uninsured patients with chronic HCV in 4 practices, quantitative data also enabled assessment of HCV staging, specialist teleconsultation, direct-acting antiviral (DAA) treatment, and sustained virologic response (SVR). Implementation fidelity and adaptation were assessed qualitatively.Anti-HCV screening was done in 13 334 of 27 700 baby boomers (48.1%, varying by practice from 19.8% to 71.3%). Of 695 anti-HCV-positive patients, HCV RNA was tested in 520 (74.8%; 48.9% to 92.9% by practice), and 349 persons (2.6% of those screened) were diagnosed with chronic HCV. In 4 FQHCs, 174 (84.9%) of 205 uninsured patients with chronic HCV had disease staging, 145 (70.7%) had teleconsultation review, 119 (58.0%) were recommended to start DAA therapy, 82 (40.0%) initiated free DAA therapy, 74 (36.1%) completed therapy (27.8% to 60.0% by practice), and 70 (94.6% of DAA completers) achieved SVR. Implementation was promoted by multilevel practice engagement, patient navigation, and anti-HCV screening with reflex HCV RNA testing.No control practices were included, and data were missing for some variables.Despite a similar framework for STOP HCC implementation, performance varied widely across safety-net practices, which may reflect practice engagement as well as infrastructure or cost challenges beyond practice control.Cancer Prevention & Research Institute of Texas and Centers for Medicare & Medicaid Services.
Pretreatment Serum Soluble Interleukin-2 Receptor Levels Predict the Response after Immunosuppressive Therapy of Aplastic Anemia.
Authors: Chang-Ki Min, Jong-Wook Lee, Woo Sung Min, Chun Choo Kim, Myungshin Kim, Jihyang Lim, Yonggoo Kim, Kyungja Han
Journal: Blood (2004)
An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)
Authors: Gregor Verhoef, Hans E Johnsen, Francesca Gaia Rossi, Antonio Salar, Lisa Hamilton, W. Marieke Schoonen, Beatriz Pujol, Ulrich Duhrsen
Journal: Blood (2008)
Molecular Progenitor Profiling in Human Myeloproliferative Disorders.
Authors: Catriona H.M. Jamieson, Jason Gotlib, Mark Chao, M Rajan Mariappan, Marla LayRaj, Carol Jones, James Zehnder, Jeffrey Durocher, Stan Lilleberg, Steven Coutre, Irving L. Weissman
Journal: Blood (2005)
Характеристика состояния кишечной микрофлоры и содержания короткоцепочечных жирных кислот у больных с синдромом раздраженного кишечника
Authors: Yu.M. Stepanov, I.Ya. Budzak, I.A. Klenina
Journal: GASTROENTEROLOGY (2019)

В статье рассматриваются вопросы, связанные с кишечной микрофлорой и короткоцепочечными жирными кислотами у больных с синдромом раздраженного кишечника. Установлено, что концентрация уксусной, пропионовой, масляной кислот в кале выше у больных с синдромом раздраженного кишечника с диареей по сравнению с больными без диарейного синдрома. У 83,3–88,9 % больных с различными формами синдрома раздраженного кишечника наблюдаются дисбиотические изменения; у пациентов с диарейной формой чаще отмечается пониженное содержание бифидобактерий и, особенно, лактобактерий. Отмечается определенная взаимозависимость между концентрацией короткоцепочечных жирных кислот и содержанием бифидобактерий, лактобактерий, кандидозной и условно-патогенной флоры.
Prospective Phase II Study of Biologic Assignment One Vs Two Unit Umbilical Cord Blood Transplant (UCBT) in the Reduced-Intensity Conditioning Setting.
Authors: Tamila L. Kindwall-Keller, Yael Hegerfeldt, Pingfu Fu, Hillard M. Lazarus, Brenda W. Cooper, Paul Barr, Stanton L. Gerson, Howard Meyerson, Sally Erinc, Richard J. Creger, Laura Fanning, Nicholas Greco, Peter Haviernik, Mathew Lesniewski, Mary J. Laughlin
Journal: Blood (2008)
Correlations Between Cytokines and Elevated Tricuspid Regurgitant Jet Velocity in Children and Adolescents with Sickle Cell Disease
Authors: Xiaomei Niu, Mehdi Nouraie, Caterina Minniti, Craig Sable, Andrew Campbell, Sohail R Rana, Gregory J. Kato, Mark Gladwin, Oswaldo Castro, Tatiana Ammosova, Sergei Nekhai, Victor R. Gordeuk
Journal: Blood (2008)
Subphenotypes of nonsteroidal antiinflammatory disease‐exacerbated respiratory disease identified by latent class analysis
Authors: Natalia Celejewska‐Wójcik, Krzysztof Wójcik, Maria Ignacak‐Popiel, Adam Ćmiel, Katarzyna Tyrak, Anna Gielicz, Aleksander Kania, Paweł Nastałek, Marek Sanak, Lucyna Mastalerz
Journal: Allergy (2019)

Abstract Background Induced sputum (IS) allows to measure mediators of asthmatic inflammation in bronchial secretions. NSAID‐exacerbated respiratory disease (NERD) is recognized as a distinct asthma phenotype, usually with a severe course, eosinophilic airway inflammation, and increased production of pro‐inflammatory eicosanoids. A more insightful analysis of NERD patients has shown this phenotype to be nonhomogeneous. Objective We aimed to identify possible subphenotypes in a cohort of NERD patients with the means of latent class analysis (LCA). Methods A total of 95 asthma patients with aspirin hypersensitivity underwent sputum induction. High‐performance liquid chromatography or gas chromatography coupled with mass spectrometry was used to profile eicosanoids in induced sputum supernatant (ISS). Sixteen variables covering clinical characteristics, IS inflammatory cells, and eicosanoids were considered in the LCA. Results Three classes (subphenotypes) were distinguished within the NERD cohort. Class 1 subjects had mild‐to‐moderate asthma, an almost equal distribution of inflammatory cell patterns, the lowest concentrations of eicosanoids, and logLTE 4 /logPGE 2 ratio. Class 2 represented severe asthma with impaired lung function despite high doses of steroids. High sputum eosinophilia was in line with higher pro‐inflammatory LTE 4 in ISS and the highest logLTE 4 /logPGE 2 ratio. Class 3 subjects had mild‐to‐moderate asthma and were also characterized by eosinophilic airway inflammation, yet increased production of pro‐ (LTE 4 , PGD 2 and 11‐dehydro‐TBX 2 ) was balanced by anti‐inflammatory PGE 2 . The value of logLTE 4 /logPGE 2 was between values calculated for classes 1 and 3, similarly to disease control and severity. Conclusions LCA revealed three distinct NERD subphenotypes. Our results support a more complex pathobiology of aspirin hypersensitivity. Considering NERD heterogeneity, the relationship between inflammatory pathways and clinical manifestations of asthma may lead to more individualized treatment in difficult to treat patients in the future.
Lineage Analysis of the FIPL1-PDGFRα Fusion Gene in Myeloproliferative Hypereosinophilic Syndrome.
Authors: Steven J. Lemery, Jamie A. Robyn, J. Philip McCoy, Joseph Kubofcik, YaeJean Kim, Thomas B. Nutman, Cynthia E. Dunbar, Amy D. Klion
Journal: Blood (2004)
Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy
Authors: Louisa von Baumgarten, Jörg Kumbrink, Andreas Jung, Anna Reischer, Madeleine Flach, Sibylle Liebmann, Klaus H. Metzeler, Julian W. Holch, Maximilian Niyazi, Niklas Thon, Andreas Straube, Michael von Bergwelt-Baildon, Volker Heinemann, Thomas Kirchner, Christoph Benedikt Westphalen
Journal: Theranostics (2019)

Background: In the era of precision medicine, cancer treatment is increasingly tailored according to tumor-specific genomic alterations. The analysis of tumor-derived circulating nucleic acids in cerebrospinal fluid (CSF) by next generation sequencing (NGS) may facilitate precision medicine in the field of CNS cancer. We therefore evaluated whether NGS from CSF of neuro-oncologic patients reliably detects tumor-specific genomic alterations and whether this may help to guide the management of patients with CNS cancer in clinical practice. Patient and methods: CSF samples from 27 patients with various primary and secondary CNS malignancies were collected and evaluated by NGS using a targeted, amplicon-based NGS-panel (Oncomine Focus Assay). All cases were discussed within the framework of a molecular tumor board at the Comprehensive Cancer Center Munich. Results: NGS was technically successful in 23/27 patients (85%). Genomic alterations were detectable in 20/27 patients (74%), 11/27 (40%) of which were potentially actionable. After discussion in the MTB, a change of therapeutic management was recommended in 7/27 (26%) of the cases. However, due to rapid clinical progression, only 4/27 (15%) of the patients were treated according to the recommendation. In a subset of patients (6/27, 22%), a high number of mutations of unknown significance suggestive of a high tumor mutational burden (TMB) were detected. Conclusions: NGS from cerebrospinal fluid is feasible in routine clinical practice and yields therapeutically relevant alterations in a large subset of patients. Integration of this approach into a precision cancer medicine program might help to improve therapeutic options for patients with CNS cancer.
Greater HLA Disparity Is Associated with Reduced Risk of Relapse and Improved Event-Free Survival after Nonmyeloablative, HLA-Haploidentical BMT with Post-Transplantation High-Dose Cyclophosphamide
Authors: Yvette L. Kasamon, Mary S. Leffell, Jeanne Kowalski, Hua-Ling Tsai, Nancy Rossiter, Lawrence E. Morris, Pamela A. Crilley, Leo Luznik, Javier Bolaños-Meade, Paul V. O’Donnell, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs
Journal: Blood (2008)
Progress Toward Regional Measles Elimination — Worldwide, 2000–2018
Authors: Minal K. Patel, Laure Dumolard, Yoann Nedelec, Samir V. Sodha, Claudia Steulet, Marta Gacic-Dobo, Katrina Kretsinger, Jeffrey McFarland, Paul A. Rota, James L. Goodson
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

In 2010, the World Health Assembly (WHA) set the following three milestones for measles control to be achieved by 2015: 1) increase routine coverage with the first dose of measles-containing vaccine (MCV1) among children aged 1 year to ≥90% at the national level and to ≥80% in every district, 2) reduce global annual measles incidence to less than five cases per 1 million population, and 3) reduce global measles mortality by 95% from the 2000 estimate* (1). In 2012, WHA endorsed the Global Vaccine Action Plan,† with the objective of eliminating measles§ in five of the six World Health Organization (WHO) regions by 2020. This report updates a previous report (2) and describes progress toward WHA milestones and regional measles elimination during 2000-2018. During 2000-2018, estimated MCV1 coverage increased globally from 72% to 86%; annual reported measles incidence decreased 66%, from 145 to 49 cases per 1 million population; and annual estimated measles deaths decreased 73%, from 535,600 to 142,300. During 2000-2018, measles vaccination averted an estimated 23.2 million deaths. However, the number of measles cases in 2018 increased 167% globally compared with 2016, and estimated global measles mortality has increased since 2017. To continue progress toward the regional measles elimination targets, resource commitments are needed to strengthen routine immunization systems, close historical immunity gaps, and improve surveillance. To achieve measles elimination, all communities and countries need coordinated efforts aiming to reach ≥95% coverage with 2 doses of measles vaccine (3).
Donor-Cell Derived Aplastic Anemia (AA) with a Small Population of CD55−CD59− Blood Cells after Allogeneic Stem Cell Transplantation: Evidence for the Immune System Attack Against Normal Hematopoietic Stem Cells in AA.
Authors: Chiharu Sugimori, Kanako Mochizuki, Hirohito Yamazaki, Shinji Nakao
Journal: Blood (2007)